Evan Norfolk is a Nephrology physician affiliated with Geisinger Commonwealth School of Medicine. OpenAlex indexes 36 publications with 1,119 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
100 N Academy Ave
Danville, PA 178221410
Telephone
570-271-6393Provider last certified this registry record 6 Aug 2020.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Baxter HealthcareProgram year20241 payment
- GENZYME CORPORATIONProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
71.6%Loop diuretic23.2%Torsemide74%Furosemide26%Part D<11 patientsCalcium channel blocker18.9%Amlodipine Besylate100%Part D≥22 patients+ 5 more classes in this area
Other
15.8%Phosphate Binder15.8%Sevelamer Carbonate100%Part D≥14 patientsBlood & clotting
4.6%Solutions for parenteral nutrition4.6%Calcium Acetate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Tumoral calcinosis in an end stage kidney disease patient on peritoneal dialysis
The American Journal of the Medical Sciences
2023 - A Self-Funded, Value-Based, Post-AKI Care Program: Predicted vs. Observed Outcomes
Journal of the American Society of Nephrology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”